Strata Skin Sciences, Inc. SSKN
We take great care to ensure that the data presented and summarized in this overview for STRATA Skin Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SSKN
Top Purchases
Top Sells
About SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Insider Transactions at SSKN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Jul 15
2024
|
Accelmed Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
230,573
+13.79%
|
$691,719
$3.14 P/Share
|
|
Jul 15
2024
|
Uri Geiger Director |
BUY
Open market or private purchase
|
Indirect |
230,573
+13.79%
|
$691,719
$3.14 P/Share
|
|
Jul 15
2024
|
Dolev Rafaeli Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
19,100
+11.77%
|
$57,300
$3.14 P/Share
|
|
Dec 01
2023
|
Shmuel Gov COO |
BUY
Open market or private purchase
|
Direct |
20,000
+18.73%
|
$0
$0.46 P/Share
|
|
Nov 16
2023
|
Samuel Rubinstein |
SELL
Open market or private sale
|
Direct |
1,000
-0.56%
|
$0
$0.32 P/Share
|
|
Aug 16
2023
|
22 Nw, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,853,056
+25.65%
|
$0
$0.55 P/Share
|
|
Aug 10
2023
|
Robert Joseph Moccia Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
42,000
+15.15%
|
$0
$0.67 P/Share
|
|
Aug 10
2023
|
Christopher Lesovitz Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,151
+18.06%
|
$0
$0.67 P/Share
|
|
Jul 05
2023
|
Samuel Rubinstein |
BUY
Grant, award, or other acquisition
|
Direct |
33,981
+15.98%
|
$33,981
$1.03 P/Share
|
|
Jul 05
2023
|
William D. Humphries |
BUY
Grant, award, or other acquisition
|
Direct |
36,408
+24.91%
|
$36,408
$1.03 P/Share
|
|
Jul 05
2023
|
Nachum Shamir |
BUY
Grant, award, or other acquisition
|
Direct |
38,835
+11.81%
|
$38,835
$1.03 P/Share
|
|
Jul 05
2023
|
Patricia S Walker |
BUY
Grant, award, or other acquisition
|
Direct |
36,408
+28.83%
|
$36,408
$1.03 P/Share
|
|
Jul 05
2023
|
Douglas Strang |
BUY
Grant, award, or other acquisition
|
Direct |
33,981
+28.12%
|
$33,981
$1.03 P/Share
|
|
Jul 01
2022
|
Nachum Shamir |
BUY
Grant, award, or other acquisition
|
Direct |
43,244
+14.69%
|
$0
$0.92 P/Share
|
|
Jul 01
2022
|
Samuel Rubinstein |
BUY
Grant, award, or other acquisition
|
Direct |
37,838
+20.74%
|
$0
$0.92 P/Share
|
|
Jul 01
2022
|
Patricia S Walker |
BUY
Grant, award, or other acquisition
|
Direct |
40,541
+35.55%
|
$0
$0.92 P/Share
|
|
Jul 01
2022
|
Douglas Strang |
BUY
Grant, award, or other acquisition
|
Direct |
37,838
+34.17%
|
$0
$0.92 P/Share
|
|
Jun 30
2022
|
Patricia S Walker |
BUY
Grant, award, or other acquisition
|
Direct |
9,756
+22.85%
|
$0
$0.96 P/Share
|
|
Jun 30
2022
|
Douglas Strang |
BUY
Grant, award, or other acquisition
|
Direct |
9,106
+20.62%
|
$0
$0.96 P/Share
|
|
Jun 15
2022
|
Samuel Rubinstein |
BUY
Open market or private purchase
|
Direct |
1,050
+0.97%
|
$1,050
$1.04 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 480K shares |
|---|